SOLIAIR

Company Overview

Snapshot

Founded in August 2012 by Solomon Jacob, SOLIAIR operates with 1–10 employees. The company secured its initial funding in September 2012, with Solomon Jacob participating as an investor. SOLIAIR ceased operations in July 2021.

Business overview

SOLIAIR is an Israeli-based alternative medicine company focused on developing natural supplements for the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory disorders. The company's core technology involves a mixture of plant extracts, which it intends to market as private-label naturopathic and homeopathic dietary supplements. SOLIAIR aims to provide alternative medicines and natural supplements, including ginseng, ginkgo, and various antioxidants, to consumers through an efficient supply chain to lower costs. It operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries.

Strategic signal

In November 2013, SOLIAIR announced a new drug discovery related to respiratory and lung diseases. This development signaled the company's early progress in identifying potential natural treatments for chronic conditions, indicating a focus on product innovation within the alternative medicine space.

Company Intelligence Q&A

When was SOLIAIR founded?

SOLIAIR was founded in August 2012.

Who founded SOLIAIR?

SOLIAIR was founded by Solomon Jacob.

What is SOLIAIR's primary focus?

SOLIAIR focuses on developing natural supplements for treating COPD and other respiratory disorders, utilizing plant extracts for naturopathic and homeopathic dietary supplements.

When did SOLIAIR cease operations?

SOLIAIR ceased to operate in July 2021.

What was a key early development for SOLIAIR?

In November 2013, SOLIAIR announced a new drug discovery related to respiratory and lung diseases, highlighting its initial research and development efforts in alternative medicine.